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Role of Pineal Hormone 
Melatonin in a Woman’s Life: From 
Conception to Decline of Life
Elena N. Usoltseva and Marina V. Danilova
Abstract
In the presented article, we cover the issues concerning physiology of secretion 
of pineal hormone melatonin and its role in the vital processes of a body. Focus is 
given to melatonin effect on the female reproductive system, its participation in the 
aging process, and formation of pathological menopause. The article also presents 
research data on the effectiveness of the melatonin drug when tackling climacteric 
syndrome. It is revealed that according to the available literature up to date there is 
no information about the standards of secretion of melatonin for women of dif-
ferent age groups, and the lack of secretion of melatonin can be judged by clinical 
manifestations and also when compared with groups of healthy women. The issues 
of the melatonin drug application at various complications of pregnancy and gyne-
cological diseases remain unclear. Long-term intake of melatonin to treat pathologic 
menopause is still to be discussed.
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1. Introduction
Melatonin is a principal hormone produced by pineal cells in the pineal gland 
located in the cerebrum center behind the third ventricle (Figure 1). This endocrine 
gland consists of two cell types: pineal cells (which dominate and produce indol-
amines, mainly represented by melatonin, and peptides, such as arginine vasotocin) 
and neuroglia cells. The information received from neurons and modified by means 
Key points
1. Melatonin functions in the human body are very diverse, and its normal secretion is extremely im-
portant for the preservation of somatic health.
2. The important role of melatonin in the formation of the reproductive function of women, the forma-
tion of a two-phase cycle, high-quality ovulation and fertilization, prevention of violations of a 
number of gynecological and obstetric pathologies.
Currently there are convincing data on the role of melatonin in the onset of menopause, the formation 
of climacteric syndrome, depression, osteoporosis, dyslipidemia, menopausal metabolic syndrome and 
cardiovascular diseases, and breast cancer in women in perimenopausal and postmenopausal women.
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of night and daylight intensity transforms in the pineal gland into chemical signals. 
Receiving the information about luminosity the pineal gland turns it into endocrine 
response by producing melatonin, which is a biogenic amine pertaining to the 
indole class, based on its chemical structure. Melatonin is a derivant of biogenic 
amine serotonin, which in its turn is synthesized from the amino acid tryptophan, 
received with food. Activity of ferments participating in serotonin transformation 
into melatonin is suppressed by lighting—that is why this hormone can be produced 
only during hours of darkness [1].
Melatonin is mainly released to the cerebrospinal fluid (liquor), getting from there 
to the blood flow and afterwards easily allocating itself in various organs and tissues 
due to good lipophilic properties [2]. Key effects of melatonin are connected with the 
action on membrane receptors—MT1 and MT2. They relate to a group of receptors 
Figure 2. 
Melatonin mechanisms of action.
Figure 1. 
Anatomical location for pineal body.
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connected with G-protein. These receptors are responsible for chronobiological 
effects and regulation of circadian rhythm and are widely distributed in different 
organs and tissues. Melatonin receptor presentation in the reproductive organs and 
receptors to sexual hormones in the epiphysis enables drawing the conclusion that 
melatonin plays an important role in regulation of reproductive aspect (Figure 2).
In the same way, the nuclear receptors of melatonin ROR-α/RZR-β have been 
discovered. It is evident that many immune-stimulating and antitumoral effects are 
mediated by them.
Antioxidative function of melatonin is based on the receptor action, but this 
hormone is able to directly withdraw free radicals without receptor actuation [3].
Russian scientists discovered that apart from epiphyseal melatonin, there is an 
extrapineal one that is formed in different gastrointestinal tracts and other organs: 
liver, kidneys, supramental capsules, gall bladder, ovaries, endometrium, placenta, 
thymus, white blood cells, thrombocytes, and endothelium. Biologic action of the 
extrapineal melatonin is carried out right where it is synthesized [1].
2.  Melatonin main physiological functions and its role in maintaining 
human health
During the recent years, new data on the mechanisms providing for the integral 
interaction among the nervous, immune, and endocrine systems have been received. 
Presumably, pineal gland is an integrator of such interaction, while its main hor-
mone, melatonin, takes part in regulation of the activity of central and vegetative 
nervous systems, endocrine organs, and immune system. The performed investiga-
tions have demonstrated that melatonin fulfills an extremely wide range of physi-
ological functions: biorhythmic and immunomodulatory processes, thermal control 
and sleep onset, and antioxidative and anti-stress effects [3]. Hormone secretion 
starts on the third month of infant development and reaches its peak during the first 
years (not later than at the age of 5). Before puberty, melatonin synthesis remains 
at a constantly high level [4]. During the age of 11–14, due to the fact that the pineal 
gland reduces melatonin production, the hormone mechanisms of sexual develop-
ment are launched. The next significant reduction in activity occurs simultaneously 
with menopause onset—at the age of 45–60. With the aging progression, along 
with decrease in basal level, melatonin secretion peaks are getting lower [1]. During 
daytime melatonin concentration in the blood serum remains low (10–20 pg/ml), 
while during the night hours it grows considerably (80,120 pg/ml) and reaches its 
maximum value between midnight and 3–5 a.m. Melatonin secretion usually starts at 
9 p.m. and terminates at 7–9 a.m. Melatonin metabolites are found in urine: 6-sulfa-
toxymelatonin (80–90%) and 6-hydroxyglucuronide (10–20%) corresponding to 
the circadian rhythm that is very close to the rhythm of melatonin secretion [5].
A new science, biorhythmology, introduced the notion of desynchronosis—
clinically very important—that means ill-being or pathological syndrome, which 
is connected with the unbalance of circadian rhythms. A degree of desynchronosis 
is defined by the quantity and rhythm of melatonin production during the day and 
night. It has been determined that when a somatic disease goes hard or aggravates, 
melatonin production is getting worse, and its night indicator is getting closer to 
the day value [6]. Disturbed melatonin secretion finds its clinical manifestation in 
tiredness, indisposition, sleep disorder, and sometimes aggravation of a chronic 
disease or even appearance of a new one. Desynchronosis condition is exemplified 
by jet lag syndrome caused by rapid long-distance transmeridian travel [7].
It is generally known that melatonin has an antidepressant function. However, 
foreign colleagues stated disturbed circadian rhythm of melatonin secretion 
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experienced by patients with depression during a menopause along with its increase 
during the morning hours as compared with women in good health that also has 
impact on sleep, level of follicle-stimulating hormone, and body mass index [8]. 
A connection was established between sleep disorder and melatonin reduction 
in female saliva during perimenopause without registering such pattern among 
women in postmenopause [9].
Therefore, melatonin functions in a human body are quite diversified, and its 
normal secretion is highly important for maintaining human health in a contempo-
rary world.
3.  Melatonin involvement into hormonal regulation of female 
reproductive system functions and its aging
In 1963 R.J. Wurtman et al. reported for the first time that exogenic intake of 
melatonin causes weight reduction in female rat ovaries. Since those times many 
evidences that pineal gland and its main hormone, melatonin, influence reproduc-
tive function have been received. Studies showed that neurons in preoptic and 
mediobasal areas of hypothalamus and hypophysis represented the main points, 
through which melatonin produced its reproductive action. The main physiologi-
cal effect of melatonin lies in the slowdown of gonadotrophin secretion, with 
greater suppression of the lutenizing hormone (LH) by melatonin rather than the 
follicle-stimulating one. Negative correlation is registered between melatonin level 
at night and lutenizing hormone concentration. In addition, secretion of other 
tropic hormones of hypophysis anterior lobe (such as corticotrophin, thyrotropin, 
somatotropin) is reduced, though to a lesser extent. Melatonin can be called a 
universal inhibitor of endocrine function in a female body [10].
Melatonin takes part in regulation of many vital physiological processes, such 
as puberty and genital formation, menstrual cycle, and aging of reproductive 
system. High level of nocturnal melatonin was found in children with delayed 
puberty, while among children having accelerated puberty, a decrease in melato-
nin secretion at night was noted. High levels of melatonin among children produce 
a dominating effect on pulsatile gonadotropin secretion, ovary function, and 
puberty [4].
Abnormal levels of melatonin in blood are connected with a number of malfunc-
tions in the system “hypothalamus—hypophysis—ovaries.” This gives boost to pre-
cocious puberty or its delay and formation of hypothalamic or hypergonadotropic 
amenorrhea. Therefore, melatonin may have indirect influence on the function of 
reproductive glands through its intervention into the secretion of gonadotropin-
releasing hormone and/or secretion of gonadotrophins. Some data demonstrate 
that melatonin can also be synthesized in reproductive glands. Decreased melatonin 
secretion in summer coincides with higher fertility among women living in the 
Northern Hemisphere [11].
Based on these data, it was presupposed that melatonin could be a part of 
events preceding activation of hypothalamus-ovary axis during a puberty period 
[12]. Non-serial MRI of female head region helped register a reliable decrease in 
pineal gland volume during the ovulatory phase as well as while perimenopause. 
It indicates pineal gland involvement into “turning off ” female reproductive 
 function [13].
Melatonin may also produce direct influence on ovaries. High level of melatonin 
was found in preovulatory follicular fluid with triple concentration as compared 
to blood. Connecting areas of iodine melatonin were identified in human cells of 
granulosis and preovulatory follicles.
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Antioxidative effect of melatonin is considered to be the most prominent one. 
It has been determined that melatonin ties free radicals of oxygen and at the same 
time stimulates enzymatic systems and SOD and possesses protective properties in 
relation to free-radical damage of DNA [14].
It’s generally known that macrofags, neutrophils, and vascular endothelium cells 
located in follicles produce AOS during ovulation. Despite the fact that AOS (active 
oxygen species) participate in breaking follicles, potentially they may damage an 
ovum and granulosis lutein cells. AOS inhibit progesterone production by lutein 
cells due to inhibition of steroidogenesis enzymes and transport intracellular 
protein. Melatonin is an important antioxidant in ovary follicles and enables proges-
terone synthesis by luteal cells [15]. Research outcomes have shown that melatonin 
intake leads to increased concentration of this hormone in follicular fluid and 
reduced oxidative damage inside follicles, thus raising a chance of fertilization and 
pregnancy [16, 17]. Melatonin intake also improved progesterone synthesis among 
women with infertility issues caused by insufficiency of the cycle luteal phase [18].
Pregnancy and acts of delivery are characterized by deep alterations in the 
endocrine profile of a female body as well as in pineal gland operation. In the case of 
physiological pregnancy, increased melatonin excretion with urine is marked, while 
just before an act of delivery its level plummets.
Decreased melatonin level is noted in the case of threatening miscarriage [4].
At the same time, many scientists speak about the great importance of mela-
tonin in the body aging process. It is also pointed out that from the age of 45, 
melatonin starts to decline steadily till the end of human life. Numerous studies 
have demonstrated the correlation between melatonin synthesis and menopause 
onset [19]. The second decrease in melatonin level may be related to involutory 
processes in pineal gland [13].
In a placebo-controlled clinical study, it was established that there was a connec-
tion between decreased content of nocturnal melatonin in saliva and menopause 
onset, while intake of 3 mg of melatonin by female patients during perimenopause 
on a daily basis for 6 months eliminates hormonal and neurovegetative disorders 
and recovers menstruation cycle and thyroid function [20].
Women in postmenopause had lower concentration of melatonin in blood serum 
as compared to women in perimenopause, with a shorter duration of melatonin 
secretion in postmenopause as a rule, while melatonin synthesis peak time (acro-
phase) was almost the same. A pattern was determined that as melatonin secre-
tion peak occurs later among women in perimenopause, anxiety level gets higher 
(p = 0.022), and as melatonin secretion continues for a longer period, the quality of 
life among patients gets better (p < 0.001) [21].
Some scientists suggest using melatonin drugs at the first stage of climacteric 
disorder treatment even before the start of hormonal therapy of menopause [4]. 
Moreover, in a double-blind placebo-controlled clinical study, it was determined 
that prescription of menopause hormonal therapy to postmenopausal women 
shifts melatonin secretion peak time without changing the melatonin level in the 
blood serum, which requires further research [21]. Other authors did not found in 
their research analyses devoted to alternative therapy for climacteric disorders any 
convincing data on hot flash arresting by melatonin drug [22].
4. Melatonin lipid metabolism
A growing number of evidences are emerging, which point to melatonin 
involvement into lipid metabolism. The study of H. Tamura was devoted to 
melatonin influence on lipid metabolism among women in perimenopause and 
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postmenopause. A negative correlation was established between nocturnal 
melatonin and total cholesterol level, low-density lipoprotein, and positive 
correlation with high-density lipoprotein. No correlation was found between 
nocturnal melatonin and triglyceride level in blood. These findings show that 
melatonin drug prescription may represent a new approach to the correction of 
lipid metabolism and prevention of cardiovascular diseases during perimenopause 
and postmenopause [23]. Other scientists determined that melatonin improves 
lipid profile (leads to a reduced level of low-density lipoprotein) and fulfills 
antioxidant protection [24].
Under a study led by L.I. Maltseva [25], scientists analyzed melatonin role in the 
development of climacteric syndrome and its effectiveness for treating pathological 
climacterium. Russian scientists established that the level of 6-sulfatoxymelato-
nin in a 24-h urine among patients with severe climacteric syndrome amounts to 
35.09 ± 3.5 ng/ml, medium severity (44.01 ± 7.92 ng/ml), and mild climacteric 
syndrome (45.91 ± 12.42 ng/ml) (1.7 times lower as compared to women in good 
health). Accordingly, secretory function of hypophysis is altered in various ways. 
Women with low level of 6-sulfatoxymelatonin in a 24-h urine show significant 
growth of both gonadotropic hormones—follicle-stimulating and luteinizing 
hormones—in a proportional way. A research showed that women had a high level 
of catecholamines (adrenaline and noradrenaline) with its degree being dependent 
on climacteric syndrome severity. It was also determined that women in perimeno-
pausal age have increased the level of atherogenic fractions of blood lipids on the 
background of lower melatonin level.
Scientists came to the conclusion that melatonin acts as a modifier of altera-
tions which occur with the development of climacteric disorders and influence 
hormonal, mediating, and biochemical indicators of the female body. Women with 
mild climacteric syndrome taking 3 mg of melatonin per day as monotherapy dem-
onstrated during the repeated evaluation of clinical, hormonal, and biochemical 
indicators after 1 month a positive dynamics of all indicators. The blood hormone 
level was close to reference values, follicle-stimulating hormone level dropped 
by 2.29 times, luteinizing hormone level by 2.1 times. Values of melatonin sulfate 
in a 24-h urine grew by 2.64 times and were close as never to the reference values 
27.95 ± 7.92…73.95 ± 24.85 ng/ml. However more significant alterations were noted 
for the severe climacteric syndrome without any side effects when melatonin treat-
ment and menopause hormonal therapy were used together [25].
5. Menopause and sleep disturbance
Japanese scientists stated that estradiol level was firmly higher among women 
that worked night shifts and went to sleep later than 1 a.m. as compared to women 
that slept at night, with the level of serum testosterone and DHEA-sulfate unaf-
fected, while 6-sulfatoxymelatonin concentration in urine was lower among 
the first group patients. Similar hormonal disruptions among postmenopausal 
women experiencing sleep disorder represent serious risk factors of breast cancer 
[26]. Singapore Chinese Health Study (2008) also showed that among women in 
postmenopause, the risk of breast cancer gets lower when sleep duration increases 
(p = 0.047). When sleep duration exceeds 9 h, a relative risk equals to 0.67 (95% 
confidence interval 0.4–1.1) as compared to women with a sleep duration of 6 h 
or less. At that, melatonin level was higher by 42% when sleep duration was 9 h 
or more. Such pattern was registered for women with normal weight (body mass 
index of 23.2 kg/m), p = 0.024 [27]. American scientists proved through a largescale 
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prospective analysis that among women with 6-sulfatoxymelatonin content within 
the upper quartile, there were fewer with invasive breast cancer than among those 
whose values were within the bottom quartile [28]. It was established that the 
increased concentration of 6-sulfatoxymelatonin in the morning urine portion 
was statistically related to a lower risk of breast cancer (ratio of chances for upper 
and lower quartiles of 6-sulfatoxymelatonin level 0.62; 95% confidence interval 
0.41–0.95; p = 0.004) [29].
C.G. Harrod and his colleagues made an assumption that a growing risk of 
cerebrovascular disease registered among menopausal women can be to some 
extent explained by changes in the level of circulating melatonin and estrogens 
and their modulating influence on biologic activity of endothelial cells, including 
vascular tone regulation, leukocytes adhesion, and angiogenesis. This hypothesis is 
confirmed by numerous studies demonstrating the braking effect of melatonin and 
estrogens on vessel tone, neuroprotection, and expression of receptors [30].
Increased melatonin secretion in the morning is more typical for menopausal 
patients with depression than women in good health. Moreover, menopause dura-
tion, level of the follicle-stimulating hormone, sleep end time, and body mass index 
may lead to alterations in melatonin secretion when suffering from depression 
during a menopause [8].
6. Melatonin effects on bone metabolism
At present a relation between melatonin and skeleton is known. Melatonin may 
produce an effect on bone tissue which manifests itself in bone tissue formation 
with osteoblasts and/or hindering bone resorption with osteoclasts. The study of 
K. Satomura et al. [31] confirms the melatonin (Mel1) receptor expression in human 
osteoblasts and tendency of its level reduction with aging. It is also demonstrated 
that melatonin can have a boosting effect on proliferation and differentiation of 
human osteoblasts [32]. Through a controlled randomized trial (2012), exogenous 
melatonin effect on bone tissue density was revealed. Bone tissue condition was 
controlled in two ways—bone tissue density estimation and bone marker deter-
mination. There was no considerable improvement noted in terms of bone tissue 
density in T points or as compared with placebo. An average change in the activity 
of bone resorption marker, N-telopeptide (NTX), in this study did not differ much 
inside and between the groups. Similarly, the average change in the activity of bone 
formation marker, osteocalcin, did not show any remarkable differences either 
inside a group or between groups. However, NTX to osteocalcin ratio followed a 
downward trend among the women who took melatonin as compared to placebo. 
It is quite important because among menopausal women, this ratio is known to 
increase so that osteoclasts activity outstrips osteoblast activity, which leads to a loss 
of bone mass. Probably, decreased level of nocturnal melatonin that occurs during 
a menopause causes hormonal unbalance and perimenopause symptoms, includ-
ing the loss in bone mass. These data prove that melatonin intake may enable the 
balancing of bone resorption and formation processes, potentially preventing fast 
loss of bone mass attributed to a menopausal period [33].
Melatonin inhibits resorption activity by reducing RANKL-mediated osteoclas-
togenesis and therefore decreases bone resorption. Melatonin also protects from 
losing bone mass induced by free radicals, which occurs in the case of extreme bone 
resorption, due to its powerful antioxidative properties [34, 35]. In addition to its 
direct effect on the bone tissue, melatonin can produce an indirect influence on 
bone metabolism through the hypothalamus-pituitary axis, by suppressing levels of 
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follicle-stimulating hormone and estrogen and increasing the level of progesterone. 
In contrast to the follicle-stimulating hormone, melatonin has positive correlation 
with progesterone level. Progesterone is known to influence on the mineral density 
of bone tissue, especially on osteoblast differentiation [36]. Reduced level of pro-
gesterone during a perimenopause may lead to the decreasing of bone tissue density 
because of osteoblasts loss.
7. Conclusion
Therefore, melatonin role in a female body is quite significant from the moment 
of birth till the last breath. It is revealed that up to the present time according to the 
literature data there is no information about the standards of secretion of melatonin 
for women of different age groups, and the lack of secretion of melatonin can be 
judged by clinical manifestations, and also when compared with groups of healthy 
women. The issues of using melatonin treatment for different cases of pregnancy 
complications and gynecological disorders remain unclear. Long-term intake of 
melatonin to treat pathological menopause is still to be discussed.
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